Liver imaging with a novel hepatitis B surface protein derived SPECT-tracer

Molecular Pharmaceutics

Volumn 10, Issue 6, 2013, Pages 2230-2236

  Müller, Thomas ^a   Mehrle, Stefan ^a   Schieck, Alexa ^a   Haberkorn, Uwe ^a   Urban, Stephan ^a   Mier, Walter ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

hepatitis B; liver; molecular imaging; radiopharmaceuticals; solid phase peptide synthesis

Indexed keywords

MERCAPTOACETYLTRIGLYCERIN; TECHNETIUM 99M; TRACER; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; FEMALE; HEPATITIS B; KIDNEY TUBULE EXCRETION; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; RAT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID PHASE SYNTHESIS; TROPISM;

ANIMALS; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; LIVER; MASS SPECTROMETRY; MICE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VIRAL ENVELOPE PROTEINS;

EID: 84878643282     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400038r     Document Type: Article

References (28)

1. Reimer, P.; Tombach, B. Hepatic MRI with SPIO: detection and characterization of focal liver lesions Eur. Radiol. 1998, 8 (7) 1198-204
2. Frydrychowicz, A.; Lubner, M. G.; Brown, J. J.; Merkle, E. M.; Nagle, S. K.; Rofsky, N. M.; Reeder, S. B. Hepatobiliary MR imaging with gadolinium-based contrast agents J. Magn. Reson. Imag. 2012, 35 (3) 492-511
3. Narita, M.; Hatano, E.; Arizono, S.; Miyagawa-Hayashino, A.; Isoda, H.; Kitamura, K.; Taura, K.; Yasuchika, K.; Nitta, T.; Ikai, I.; Uemoto, S. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma J. Gastroenterol. 2009, 44 (7) 793-8
4. Tsuboyama, T.; Onishi, H.; Kim, T.; Akita, H.; Hori, M.; Tatsumi, M.; Nakamoto, A.; Nagano, H.; Matsuura, N.; Wakasa, K.; Tomoda, K. Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging - correlation with expression of sinusoidal and canalicular transporters and bile accumulation Radiology 2010, 255 (3) 824-33
5. Talbot, J. N.; Fartoux, L.; Balogova, S.; Nataf, V.; Kerrou, K.; Gutman, F.; Huchet, V.; Ancel, D.; Grange, J. D.; Rosmorduc, O. Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease J. Nucl. Med. 2010, 51 (11) 1699-706
6. Araikum, S.; Mdaka, T.; Esser, J. D.; Zuckerman, M. Hepatobiliary kinetics of technetium-99m-IDA analogs: quantification by linear systems theory J. Nucl. Med. 1996, 37 (8) 1323-30
7. Gripon, P.; Cannie, I.; Urban, S. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein J. Virol. 2005, 79 (3) 1613-22
8. Petersen, J.; Dandri, M.; Mier, W.; Lutgehetmann, M.; Volz, T.; von Weizsacker, F.; Haberkorn, U.; Fischer, L.; Pollok, J. M.; Erbes, B.; Seitz, S.; Urban, S. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein Nat. Biotechnol. 2008, 26 (3) 335-41
9. Schulze, A.; Schieck, A.; Ni, Y.; Mier, W.; Urban, S. Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction J. Virol. 2010, 84 (4) 1989-2000
10. Meier, A.; Mehrle, S.; Weiss, T. S.; Mier, W.; Urban, S. The myristoylated pre-S1-domain of the hepatitis B virus L-protein mediates specific binding todifferentiated hepatocytes Hepatology 2012, 10.1002/hep.26181
11. Schieck, A.; Schulze, A.; Gahler, C.; Muller, T.; Haberkorn, U.; Alexandrov, A.; Urban, S.; Mier, W. Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts Hepatology 2013, 10.1002/hep.26211
12. Schieck, A.; Muller, T.; Schulze, A.; Haberkorn, U.; Urban, S.; Mier, W. Solid-phase synthesis of the lipopeptide Myr-HBVpreS/2-78, a hepatitis B virus entry inhibitor Molecules 2010, 15 (7) 4773-83
13. Okarvi, S. M.; Adriaens, P.; A., V. Comparison of the labelling characteristics of mercaptoacetyltriglycine (MAG3) with different S-protective groups J. Labelled Compounds Radiopharm. 1997, 39 (10) 853-74
14. Gripon, P.; Rumin, S.; Urban, S.; Le Seyec, J.; Glaise, D.; Cannie, I.; Guyomard, C.; Lucas, J.; Trepo, C.; Guguen-Guillouzo, C. Infection of a human hepatoma cell line by hepatitis B virus Proc. Natl. Acad. Sci. U.S.A. 2002, 99 (24) 15655-60
15. Kreamer, B. L.; Staecker, J. L.; Sawada, N.; Sattler, G. L.; Hsia, M. T.; Pitot, H. C. Use of a low-speed, iso-density Percoll centrifugation method to increase the viability of isolated rat hepatocyte preparations In Vitro Cell Dev. Biol. 1986, 22 (4) 201-11
16. Lebl, M.; Krchnak, V.; Lebl, G. Peptide Companion; CSPS Pharmaceuticals: San Diego, CA, 1995.
17. Muhlhausen, U.; Schirrmacher, R.; Piel, M.; Lecher, B.; Briegert, M.; Piee-Staffa, A.; Kaina, B.; Rosch, F. Synthesis of 131I-labeled glucose-conjugated inhibitors of O6-methylguanine-DNA methyltransferase (MGMT) and comparison with nonconjugated inhibitors as potential tools for in vivo MGMT imaging J. Med. Chem. 2006, 49 (1) 263-72
18. Holder, L. E.; Saenger, E. L. The use of nuclear medicine in evaluating liver disease Semin. Roentgenol. 1975, 10 (3) 215-22
19. Popperl, G.; Helmberger, T.; Munzing, W.; Schmid, R.; Jacobs, T. F.; Tatsch, K. Selective internal radiation therapy with SIR-Spheres in patients with nonresectable liver tumors Cancer Biother. Radiopharm. 2005, 20 (2) 200-8
20. Haug, A. R.; Tiega Donfack, B. P.; Trumm, C.; Zech, C. J.; Michl, M.; Laubender, R.; Uebleis, C.; Bartenstein, P.; Heinemann, V.; Hacker, M. 18F-FDG PET/CT Predicts Survival After Radioembolization of Hepatic Metastases from Breast Cancer J. Nucl. Med. 2012, 53, 371-7
21. Schwarzrock, R.; Kotzerke, J.; Hundeshagen, H.; Bocker, K.; Ringe, B. 99mTc-diethyl-iodo-HIDA (JODIDA): a new hepatobiliary agent in clinical comparison with 99mTc-diisopropyl-HIDA (DISIDA) in jaundiced patients Eur. J. Nucl. Med. 1986, 12 (7) 346-50
22. Russell-Jones, D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue Mol. Cell. Endocrinol. 2009, 297 (1-2) 137-40
23. Ryan, G. J.; Foster, K. T.; Jobe, L. J. Review of the therapeutic uses of liraglutide Clin. Ther. 2011, 33 (7) 793-811
24. Wang, Q.; Graham, K.; Schauer, T.; Fietz, T.; Mohammed, A.; Liu, X.; Hoffend, J.; Haberkorn, U.; Eisenhut, M.; Mier, W. Pharmacological properties of hydrophilic and lipophilic derivatives of octreotate Nucl. Med. Biol. 2004, 31 (1) 21-30
25. Jimenez, R. H.; Boylan, J. M.; Lee, J. S.; Francesconi, M.; Castellani, G.; Sanders, J. A.; Gruppuso, P. A. Rapamycin response in tumorigenic and non-tumorigenic hepatic cell lines PLoS One 2009, 4 (10) e7373
26. Glebe, D.; Urban, S. Viral and cellular determinants involved in hepadnaviral entry World J. Gastroenterol. 2007, 13 (1) 22-38
27. Schulze, A.; Mills, K.; Weiss, T. S.; Urban, S. Hepatocyte polarization is essential for the productive entry of the hepatitis B virus Hepatology 2012, 55 (2) 373-83
28. Frangioni, J. V. New technologies for human cancer imaging J. Clin. Oncol. 2008, 26 (24) 4012-21